N-Propyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzamide

Catalog No. :
ACTGTP830
CAS No. :
2490666-07-2
Molecular Formula :
C16H24BNO3
Molecular Weight :
289.18

IUPAC Name:N-propyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzamide

N-Propyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzamide structure diagram
Pack SizePurityList PriceYour PriceGlobal StockUS StockQuantity
250mg95%$97.00Login to see priceInquiryInquiry
1g95%$203.00Login to see priceInquiryInquiry
5g95%$756.00Login to see priceInquiryInquiry

Products of AiFChem are all designed for scientific research only. Under no circumstances do we provide products or services for animal or personal utilization.

Product Information

Product NameN-Propyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzamide
IUPAC NameN-propyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzamide
MDL No.MFCD24039445
Molecular FormulaC16H24BNO3
Molecular Weight289.18
SMILESO=C(NCCC)C1=CC=C(B2OC(C)(C)C(C)(C)O2)C=C1
InChI KeySLFUENODDJHKRT-UHFFFAOYSA-N
SynonymBenzamide, N-propyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-
CAS No.2490666-07-2

Safety Data

Pictogram
Harmful or irritant
Signal Word
Achtung
Hazard Statement(s)
H302-H315-H319-H335
Precautionary Statement(s)
P261-P264-P270-P271-P280-P302+P352-P304+P340-P305+P351+P338-P312-P330-P362-P403+P233-P501

Synthetic Route by SureRoute

1. ACTGTP830 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. ACTOBU801 route compound structure diagram
    ACTOBU80173183-34-3 In Stock
  2. Plus
  3. reactant_2 route compound structure diagram
    --
  4. Then
  5. ACTGTP830 route product structure diagram
    ACTGTP8302490666-07-2
Inquiry

2. ACTGTP830 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. ACFXIR245 route compound structure diagram
    ACFXIR245180516-87-4 In Stock
  2. Plus
  3. ACGTAQ598 route compound structure diagram
    ACGTAQ598556-53-6 In Stock
  4. Then
  5. ACTGTP830 route product structure diagram
    ACTGTP8302490666-07-2
Inquiry

Comments (0)